Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Shield Therapeutics ( (GB:STX) ).
Shield Therapeutics reported a Q1 2025 trading update with net revenues of $6.4 million from ACCRUFeR® prescriptions, despite early challenges such as weather disruptions and sales force vacancies. The company remains optimistic about becoming cash flow positive by the end of 2025, with March showing significant recovery in sales. Shield is focused on expanding its global market presence and has secured an amendment to its existing $20 million debt financing agreement to improve revenue covenants.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). The company has established collaborations for the distribution of its product in the U.S. and has licensed rights to various pharmaceutical companies across Europe, Asia, and Canada.
YTD Price Performance: -1.85%
Average Trading Volume: 2,477,656
Technical Sentiment Signal: Strong Buy
Current Market Cap: £29.17M
See more insights into STX stock on TipRanks’ Stock Analysis page.